Chinese Firm Sinopharm’s COVID-19 Vaccine Shows 86% Efficacy in Late-Stage Trials

By HospiMedica International staff writers
Posted on 11 Dec 2020

An interim analysis of the Phase 3 trials of China National Pharmaceutical Group Co., Ltd.’s (Sinopharm Beijing, China) inactivated COVID-19 vaccine has shown the vaccine to have 86% efficacy against COVID-19 infection.

The analysis has also shown the vaccine to have 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease. Furthermore, the analysis showed no serious safety concerns. The UAE’s Ministry of Health and Prevention, MOHAP, in collaboration with the Department of Health Abu Dhabi, DOH, reviewed Sinopharm’s interim analysis of the Phase 3 trials. The #4Humanity Phase 3 trials have included 31,000 volunteers across 125 nationalities in the UAE alone.

Image: H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of Department of Health, Abu Dhabi, being administered the world’s first clinical Phase III trial of inactivated vaccine to combat COVID-19 (Photo courtesy of AETOSWire).

MOHAP has announced the official registration of Sinopharm’s inactivated COVID-19 vaccine in response to the application from the Chinese firm. This vaccine was granted Emergency Use Authorization (EUA) since September by MOHAP to protect frontline workers most at risk of COVID-19. The UAE is conducting Post Authorization Safety Study, PASS, and Post Authorization Efficacy Study, PAES, of its EUA program. These ongoing studies demonstrate similar safety and efficacy profiles as the interim analysis.

Related Links:
China National Pharmaceutical Group Co., Ltd.